Table 1.

Performance characteristics of early response criteria for disease activity outcomes at Week 24 (DMARD-IR population).

Week 24 Outcomes, %
	DAS28 = 3.2				DAS28 < 2.6				CDAI = 10				SDAI = 11
≥ 50% SJC66 improvement by Week 8
	Sensitivity	Specificity	PPV	NPV	Sensitivity	Specificity	PPV	NPV	Sensitivity	Specificity	PPV	NPV	Sensitivity	Specificity	PPV	NPV
Placebo + DMARD	69	63	9	98	80	63	4	99	70	66	19	95	70	66	19	95
TCZ 4 mg/kg + DMARD	71	52	31	85	76	50	17	94	75	55	39	85	78	56	39	87
TCZ 8 mg/kg + DMARD	68	56	51	72	71	53	35	84	75	56	44	83	75	57	46	82
Rapid3 at least moderate response by Week 8
Placebo + DMARD	67	52	6	97	75	51	3	99	65	52	14	93	64	52	13	93
TCZ 4 mg/kg + DMARD	75	42	29	84	76	40	15	92	73	42	32	80	73	42	32	81
TCZ 8 mg/kg + DMARD	78	41	47	73	80	38	31	84	78	38	37	79	77	39	38	77

CDAI: Clinical Disease Activity Index; DAS28: Disease Activity Score using 28 joints; DMARD-IR: DMARD inadequate response; NPV: negative predictive value; PPV: positive predictive value; RAPID3: Routine Assessment of Patient Index Data 3; SDAI: Simplified Disease Activity Index; SJC66: swollen joint count based on 66 joints; TCZ: tocilizumab.